DANA-FARBER CANCER INSTITUTE INC
450 BROOKLINE AVE, Boston, MA 02215 www.dana-farber.org

---

Organizations Filed Purposes: THE MISSION OF DANA-FARBER CANCER INSTITUTE IS TO OPERATE, CONDUCT AND SUPPORT AN INSTITUTE FOR RESEARCH INTO THE CAUSES, TREATMENT AND PREVENTION OF CANCER AND OTHER DISEASES IN CHILDREN AND ADULTS AND TO PROVIDE FOR THE CARE, TREATMENT AND NURSING OF PERSONS HAVING SUCH DISEASES, AND IN FURTHERANCE OF THE FOREGOING, TO CONSTRUCT, OPERATE AND MAINTAIN A HOSPITAL OR HOSPITALS, A CANCER CENTER AND OTHER FACILITIES IN BOSTON, MASSACHUSETTS, ANYWHERE IN THE UNITED STATES OF AMERICA OR ELSEWHERE IN THE WORLD TO PROVIDE FOR PERSONS WITH CANCER AND OTHER DISEASES REGARDLESS OF AGE; TO PROMOTE HEALTH CARE IN COMMUNITIES AROUND THE WORLD BY EDUCATING AND SUPPORTING OTHER PROVIDERS IN EFFECTIVE CANCER CARE AND RESEARCH; AND TO CARRY ON ALL ACTIVITIES RELATED OR INCIDENT THERETO INCLUDING, BUT WITHOUT LIMITATION HERETO, RESEARCH, STUDY, TEACHING, CLINICAL INVESTIGATION, CARE OF PATIENTS AND TRAINING OF MEDICAL STUDENTS, SCIENTISTS, NURSES, RESEARCH ASSISTANTS AND PARAMEDICAL PERSONNEL.

THE MISSION OF DFCI IS TO PROVIDE EXPERT, COMPASSIONATE CARE TO CHILDR COMPASSIONATE CARE TO CHILDREN AND ADULTS WITH CANCER & ADVANCE THE TREATMENT, CURE, AND PREVENTION OF CANCER & RELATED DISEASES.

CLINICAL CARE AS ONE OF THE LEADING CANCER CENTERS IN THE WORLD, DANA-FARBER CANCER INSTITUTE (DFCI) PROVIDES COMPASSIONATE, COMPREHENSIVE, AND PERSONALIZED CARE TO ADULTS AND CHILDREN WITH CANCER, BLOOD DISORDERS, AND RELATED DISEASES. IN FISCAL YEAR 2019, OUR EXPERT CLINICIANS AND CAREGIVERS AT OUR SPECIALIZED TREATMENT CENTERS WORKED TOGETHER TO DELIVER THE LATEST THERAPIES TO OUR PATIENTS THROUGH 1,568 INPATIENT ADMISSIONS, 359,519 OUTPATIENT MD VISITS, AND 187,664 INFUSION TREATMENTS. SINCE ITS FOUNDING IN 1947 BY SIDNEY FARBER, MD, DANA-FARBER HAS FOLLOWED HIS VISION FOR A CANCER CENTER THAT IS JUST AS DEDICATED TO DISCOVERIES IN CANCER RESEARCH AS IT IS TO DELIVERING EXPERT, COMPASSIONATE CARE. DANA-FARBER IS A FOUNDING MEMBER OF DANA-FARBER/HARVARD CANCER CENTER AND ONE OF 51 NCI-DESIGNATED COMPREHENSIVE CANCER CENTERS IN THE U.S. DANA-FARBER IS THE ONLY HOSPITAL RANKED IN THE TOP FOUR NATIONALLY BY U.S NEWS AND WORLD REPORT IN BOTH ADULT AND PEDIATRIC CANCER CARE. IN 2019, WE OFFERED MORE THAN 1,100 CLINICAL TRIALS.

RESEARCH SCIENTIFIC WORK AT DANA-FARBER IS BASED ON THE PREMISE THAT BASIC AND CLINICAL INVESTIGATION ARE COMPLEMENTARY AND REINFORCING ACTIVITIES. TO ENCOURAGE THIS CROSS-POLLINATION OF IDEAS, THE INSTITUTE HAS DEVELOPED AN ORGANIZATIONAL FRAMEWORK THAT FOSTERS COLLABORATIONS AMONG INVESTIGATORS FROM DIFFERENT DISCIPLINES. THE RESULT IS AN INTENSE SCIENTIFIC IMPACT ON A GROUP OF DISEASES THAT CONTINUE TO REPRESENT ONE OF HUMANITYS GREATEST HEALTH CHALLENGES. SOME RECENT ADVANCES INCLUDE: OVERCOMING RESISTANCE TO IMMUNOTHERAPY: A TEAM OF RESEARCHERS AT DANA-FARBER AND THE BROAD INSTITUTE OF MIT AND HARVARD IDENTIFIED A PATTERN OF GENE ACTIVITY IN HUMAN MELANOMA CELLS THAT ENABLES THEM TO RESIST IMMUNOTHERAPY. THE RESEARCHERS DEMONSTRATED THAT A COMBINATION OF THERAPIES COULD OVERCOME THIS RESISTANCE. PARP INHIBITORS OPEN TWO-FRONT ATTACK ON CANCER: DANA-FARBER RESEARCHERS SHOWED THAT PARP INHIBITORS DRUGS DESIGNED TO KILL CANCER CELLS BY HINDERING THE REPAIR OF DNA CAN ALSO SPARK AN IMMUNE SYSTEM ATTACK ON SUCH CELLS. PREVENTIVE SURGERY AND QUALITY OF LIFE: AS MORE YOUNG WOMEN WITH BREAST CANCER OPT TO HAVE MASTECTOMIES, MANY EXPERIENCE A PERSISTENT DECLINE IN THEIR SEXUAL AND PSYCHOSOCIAL WELL-BEING, DANA-FARBER INVESTIGATORS REPORTED. THE FINDINGS UNDERSCORED THE IMPORTANCE OF COUNSELING PATIENTS ABOUT THE POTENTIAL LONG-TERM PHYSICAL AND EMOTIONAL CONSEQUENCES OF THE PROCEDURE. BLOOD TEST FOR CANCER: IN TESTS LED BY DANA-FARBER RESEARCHERS, A NEW BLOOD TEST SCREENED FOR NUMEROUS TYPES OF CANCER WITH A HIGH DEGREE OF ACCURACY. THE TEST USES NEXT-GENERATION TECHNOLOGY TO PROBE DNA WITHIN BLOOD FOR CHEMICAL TAGS CALLED METHYL GROUPS THAT INFLUENCE GENE ACTIVITY. ONE-TIME EDUCATION CLASS FOR CHRONIC INSOMNIA: DANA-FARBER INVESTIGATORS REPORTED THAT A SINGLE-SESSION SLEEP EDUCATION PROGRAM COULD OFTEN CURE CANCER SURVIVORS OF CHRONIC INSOMNIA A COMMON PROBLEM AMONG SURVIVORS AND THAT THOSE WHO DIDNT BENEFIT WERE OFTEN HELPED BY A MORE EXTENSIVE, BUT STILL MODEST, THREE-SESSION PROGRAM. EXPOSURE TO SECOND-HAND VAPOR FROM E-CIGARETTES: A GROWING NUMBER OF MIDDLE- AND HIGH-SCHOOL STUDENTS ARE BEING EXPOSED TO SECOND-HAND AEROSOLS FROM E-CIGARETTES BY LIVING WITH OR BEING AROUND INDIVIDUALS WHO ARE VAPING, ACCORDING TO A DANA-FARBER ANALYSIS OF NATIONAL SURVEY DATA. EXERCISE BENEFITS PATIENTS WITH ADVANCED COLORECTAL CANCER: PATIENTS WITH METASTATIC COLORECTAL CANCER WHO ENGAGED IN MODERATE EXERCISE WHILE UNDERGOING CHEMOTHERAPY TENDED TO HAVE DELAYED PROGRESSION OF THEIR DISEASE AND FEWER SIDE EFFECTS FROM TREATMENT, A STUDY BY DANA-FARBER AND BRIGHAM AND WOMENS HOSPITAL RESEARCHERS FOUND. ARTIFICIAL INTELLIGENCE TOOL SHOWS PROMISE: SCIENTISTS AT DANA-FARBER DEMONSTRATED THAT AN ARTIFICIAL INTELLIGENCE TOOL COULD PERFORM AS WELL AS HUMAN REVIEWERS AND MUCH MORE RAPIDLY IN EXTRACTING CLINICAL INFORMATION ON CHANGES IN TUMORS FROM UNSTRUCTURED RADIOLOGY REPORTS FOR PATIENTS WITH LUNG CANCER. THE TOOL PERFORMED COMPARABLY TO TRAINED HUMAN CURATORS IN DETECTING THE PRESENCE OF CANCER AND ITS RESPONSE TO TREATMENT. IMMUNOTHERAPY AND SECOND DRUG SHOW EFFECTIVENESS IN OVARIAN CANCER: A COMBINATION OF AN IMMUNOTHERAPY DRUG AND A DNA REPAIR-BLOCKING AGENT CAN BE SIGNIFICANTLY MORE EFFECTIVE THAN EITHER DRUG ALONE IN WOMEN WITH HARD-TO-TREAT OVARIAN CANCER, A CLINICAL TRIAL LED BY DANA-FARBER RESEARCHERS INDICATED. THE TRIAL OFFERED EVIDENCE THAT IMMUNOTHERAPIES, WHICH RARELY HAVE AN IMPACT AGAINST OVARIAN CANCER AS SINGLE AGENTS, COULD PRODUCE A POWERFUL ANTI-CANCER RESPONSE IN TANDEM WITH OTHER DRUGS. WALKING SPEED AND OUTCOMES IN OLDER PATIENTS: RESEARCHERS AT DANA-FARBER AND THE VA BOSTON HEALTHCARE SYSTEM UNCOVERED A NEW VITAL SIGN FOR GAUGING SURVIVAL AND LIKELIHOOD OF HAVING AN UNPLANNED HOSPITALIZATION IN OLDER PATIENTS WITH BLOOD CANCERS: THE SPEED AT WHICH THEY CAN WALK. THE RESEARCHERS REPORTED THAT FOR EVERY 0.1 METER PER SECOND DECREASE IN HOW FAST PATIENTS WALK FOUR METERS, THE RISK OF DYING, UNEXPECTEDLY GOING TO THE HOSPITAL, OR USING THE EMERGENCY ROOM ROSE. COMBINATION THERAPY FOR KIDNEY CANCER APPROVED: BASED ON A CLINICAL TRIAL CO-LED BY DANA-FARBER INVESTIGATORS, AN IMMUNOTHERAPY DRUG COMBINATION WON APPROVAL AS A STANDARD FIRST-LINE THERAPY FOR PATIENTS WITH ADVANCED CLEAR CELL RENAL CELL CARCINOMA, THE MOST COMMON FORM OF KIDNEY CANCER. BENEFITS OF HIGH-DOSE VITAMIN D: SUPPLEMENTING CHEMOTHERAPY WITH HIGH DOSES OF VITAMIN D MAY BENEFIT PATIENTS WITH METASTATIC COLORECTAL CANCER BY DELAYING PROGRESSION OF THE DISEASE, A SMALL CLINICAL TRIAL LED BY DANA-FARBER INVESTIGATORS SUGGESTED. LONG-TERM MARIJUANA SMOKING AND PULMONARY DISEASE: HIV-INFECTED MEN WHO SMOKE MARIJUANA FOR SEVERAL YEARS ARE AT HEIGHTENED RISK OF DEVELOPING BOTH INFECTIOUS AND NON-INFECTIOUS LUNG DISEASES, REGARDLESS OF WHETHER THEY ALSO SMOKE TOBACCO PRODUCTS, RESEARCHERS AT DANA-FARBER REPORTED. THE FINDINGS SUGGESTED THAT HEALTHCARE PROVIDERS CAN HAVE AN IMPORTANT ROLE IN REDUCING THE RISK OF CERTAIN LUNG DISEASES IN HIV-POSITIVE PATIENTS BY COUNSELING THEM ABOUT THE POTENTIAL HARM OF MARIJUANA SMOKING ON LUNG HEALTH.

COMMUNITY BENEFITS THE ROLE OF DANA-FARBER'S COMMUNITY BENEFITS OFFICE IS TO SUPPORT THE INSTITUTE'S GOAL TO REDUCE CANCER RISK AMONG MEDICALLY UNDERSERVED POPULATIONS. TO THAT END, WE WORK WITH CITY AND STATE HEALTH DEPARTMENTS, COMMUNITY PARTNERS, AND BOSTON-BASED COALITIONS TO ASSESS AND MONITOR THE NEEDS OF LOCAL RESIDENTS WITH RESPECT TO CANCER CONTROL. WE ARE ON THE FRONT LINES OF SUPPORTING AND COLLABORATING ON PROGRAMS DESIGNED TO ELIMINATE DISPARITIES IN BREAST, COLON, SKIN, AND PROSTATE CANCER; EDUCATE DIVERSE POPULATIONS ABOUT TOBACCO CESSATION, HUMAN PAPILLOMAVIRUS (HPV) PREVENTION AND SCREENING, AND CLINICAL TRIALS; AND STRENGTHEN THE SUPPORT SYSTEM FOR MEDICALLY UNDERSERVED POPULATIONS. IN SHORT, WE ARE COMMITTED TO MAKING DANA-FARBER'S CARE AND RESEARCH FINDINGS ARE MORE ACCESSIBLE TO EVERYONE WITHIN AND OUTSIDE ITS WALLS. IN FY 2019: DANA-FARBERS MAMMOGRAPHY SERVICES PROVIDED CLOSE TO 2,400 MAMMOGRAMS ON THE VAN AND AT THE MAMMOGRAPHY SUITE IN ROXBURY. 1,086 INDIVIDUALS RECEIVED BREAST HEALTH EDUCATION ON THE MAMMOGRAPHY VAN OR AT A COMMUNITY OUTREACH EVENT. A TOTAL OF 61 COMMUNITY MEMBERS HAVE BEEN TRAINED AS LAY HEALTH ADVISORS IN BREAST CANCER, SCREENING GUIDELINES, AND HEALTH PROMOTION AND OUTREACH STRATEGIES. 1,659 COMMUNITY MEMBERS WERE REACHED THROUGH SUN SAFETY EDUCATION AND SCREENING EVENTS, WITH AN AVERAGE OF 59 PARTICIPANTS PER EVENT. A TOTAL OF 3,354 INDIVIDUALS WERE REACHED THROUGH 146 COMMUNITY EDUCATION, OUTREACH AND SCREENING EVENTS.

---

---

Data for this page was sourced from XML published by IRS (public 990 form dataset) from: https://s3.amazonaws.com/irs-form-990/202012259349300536_public.xml